Showing results (261-270 of 271) with videos related to

Sort By:
Pageof 28
Neuro-Oncology|April 28, 2025
Establishing the content validity of Patient-Reported Outcome measures used in neuro-oncology based on the WHO ICF framework: part of the RANO-PRO initiativeOgechukwu A Asogwa, Linda Dirven, Tobias Walbert, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 8, 2022
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendationScott R Plotkin, Ludwine Messiaen, Eric Legius, et al.
American Journal of Medical Genetics. Part A|March 26, 2019
First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeuticsKatherine A Rauen, Abeer Alsaegh, Shay Ben-Shachar, et al.
Plos One|June 14, 2018
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2, Robert Allaway, Steve P Angus, et al.
Neuro-Oncology|July 5, 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensusPeter M K de Blank, Andrea M Gross, Srivandana Akshintala, et al.
Nature Medicine|January 14, 2021
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trialMichael J Fisher, Chie-Schin Shih, Steven D Rhodes, et al.
American Journal of Medical Genetics. Part A|January 21, 2014
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapiesBrigitte C Widemann, Maria T Acosta, Sylvia Ammoun, et al.
Magnetic Resonance in Medicine|April 22, 2022
Review and consensus recommendations on clinical APT-weighted imaging approaches at 3T: Application to brain tumorsJinyuan Zhou, Moritz Zaiss, Linda Knutsson, et al.
American Journal of Medical Genetics. Part A|March 16, 2026
The 9th International RASopathies SymposiumPau Castel, Lisa Schoyer, Beth Stronach, et al.
Plos One|July 15, 2021
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALKLong-Sheng Chang, Janet L Oblinger, Abbi E Smith, et al.
Pageof 28